more conservative dosing for renal patients using erythropoiesis-stimulating agents

You'll see more conservative dosing for renal patients using erythropoiesis-stimulating agents...Procrit, Epogen, Aranesp.

FDA no longer recommends targeting a specific hemoglobin concentration for these drugs in chronic kidney disease patients.

There's not an additional benefit to aiming for a hemoglobin over 11 g/dL...and it increases the risk of heart attack, stroke, and death.